Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Nuvalent, Inc. (United States)
Homepage:
nuvalent.com
Alternate names:
Nuvalent,
Nuvalent, Inc.
ROR:
00t08q103
OpenAlex ID:
I4405264046
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
2024
·
Jessica J. Lin
, Joshua C. Horan
, et al.
·
Cancer Discovery
·
69
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
2022
·
Alexander Drilon
, Joshua C. Horan
, et al.
·
Cancer Discovery
·
55
In silico approaches in organ toxicity hazard assessment: Current status and future needs for predicting heart, kidney and lung toxicities
2021
·
Arianna Bassan
, Vinicius M. Alves
, et al.
·
Computational Toxicology
·
48
In silico approaches in organ toxicity hazard assessment: Current status and future needs in predicting liver toxicity
2021
·
Arianna Bassan
, Vinicius M. Alves
, et al.
·
Computational Toxicology
·
47
Principles and procedures for assessment of acute toxicity incorporating in silico methods
2022
·
Craig M. Zwickl
, Jessica C. Graham
, et al.
·
Computational Toxicology
·
33
PDF
Abstract 1468: NUV-655 (NVL-655) is a selective, brain-penetrant ALK inhibitor with antitumor activity against the lorlatinib-resistant G1202R/L1196M compound mutation
2021
·
Henry E. Pelish
, Anupong Tangpeerachaikul
, et al.
·
Cancer Research
·
26
1253O Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours
2024
·
A.E. Drilon
, J.J. Lin
, et al.
·
Annals of Oncology
·
23
PDF
1256MO Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours
2024
·
B. Besse
, A.E. Drilon
, et al.
·
Annals of Oncology
·
19
PDF
The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study
2022
·
David J. Benjamin
, Shuai Chen
, et al.
·
JTO Clinical and Research Reports
·
13
PDF
Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors
2022
·
A. Drilon
, B. Besse
, et al.
·
European Journal of Cancer
·
12
PDF
Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025
·
Anupong Tangpeerachaikul
, Scot Mente
, et al.
·
Molecular Cancer Therapeutics
·
10
PDF
81TiP NVL-655, a selective anaplastic lymphoma kinase (ALK) inhibitor, in patients with advanced ALK-positive solid tumors: The phase I/II ALKOVE-1 study
2023
·
M.L. Johnson
, S-H.I. Ou
, et al.
·
Journal of Thoracic Oncology
·
8
PDF
Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study.
2025
·
Sanjay Popat
, Benjamin J. Solomon
, et al.
·
Journal of Clinical Oncology
·
6
Abstract B154: Safety and preliminary activity of the selective ALK inhibitor NVL-655 in patients with ALK fusion-positive solid tumors
2023
·
Jessica J Lin
, Melissa Johnson
, et al.
·
Molecular Cancer Therapeutics
·
5
ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced ALK + NSCLC.
2026
·
Jessica Jiyeong Lin
, Enriqueta Felip
, et al.
·
Journal of Clinical Oncology
·
4
PDF
Abstract 1979: Preclinical characterization of NVL-330, a selective and brain penetrant HER2 tyrosine kinase inhibitor with broad activity on HER2 oncogenic alterations
2024
·
Yuting Sun
, Kristin L. Andrews
, et al.
·
Cancer Research
·
4
Abstract P244: NVL-655 exhibits antitumor activity in lorlatinib-resistant and intracranial models of ALK-rearranged NSCLC
2021
·
Anupong Tangpeerachaikul
, Amit Deshpande
, et al.
·
Molecular Cancer Therapeutics
·
4
Abstract 1465: NUV-520 (NVL-520) is a brain-penetrant and highly selective ROS1 inhibitor with antitumor activity against the G2032R solvent front mutation
2021
·
Henry E. Pelish
, Anupong Tangpeerachaikul
, et al.
·
Cancer Research
·
4
Abstract CT248: Zidesamtinib in patients with ROS1+ NSCLC previously treated with repotrectinib or taletrectinib
2026
·
Geoffrey Liu
, Alexander E. Drilon
, et al.
·
Cancer Research
·
2
CDK8 /19 inhibition triggers a switch from mitosis to endomitosis in cord blood megakaryocytes
2024
·
Zhi‐Jian Liu
, Christopher Thom
, et al.
·
British Journal of Haematology
·
2
PDF
Preclinical activity of NVL-655 in patient-derived models of ALK cancers, including those with lorlatinib-resistant G1202R/L1196M compound mutation
2022
·
T. Fujino
, L. Nguyen
, et al.
·
European Journal of Cancer
·
2
PDF
EP08.02-020 Preclinical Activity of NVL-655 in a Patient-Derived NSCLC Model with Lorlatinib-Resistant ALK G1202R/T1151M Mutation
2022
·
H. Mizuta
, L. Bigot
, et al.
·
Journal of Thoracic Oncology
·
2
PDF
Abstract 3337: Preclinical activity of NVL-655 in ALK-driven cancer models beyond non-small cell lung cancer
2022
·
Anupong Tangpeerachaikul
, Ludovic Bigot
, et al.
·
Cancer Research
·
2
PL03.06: Zidesamtinib in TKI-naive Patients with Advanced/Metastatic ROS1+ NSCLC: ARROS-1 Efficacy and Safety Data
2026
·
A. Drilon
, A.J. de Langen
, et al.
·
Journal of Thoracic Oncology
·
1
Zidesamtinib efficacy and safety in patients with advanced ROS1 -positive solid tumors other than NSCLC in the ARROS-1 study.
2026
·
Benjamin J. Solomon
, Sanjay Popat
, et al.
·
Journal of Clinical Oncology
·
1
Show more works
View as search
Works count:
45
Citation count:
1,834
Year
Topic
Type
